37.89
+2.29%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vineet Laboratories
Its shares trade on NSE under the ticker VINEETLAB.NS. It has been listed since 15 June 2021. In the fiscal year to 31 March 2026, it reported revenue of ₹594.0m and net income of ₹11.1m. At that date it held total assets of ₹1.25bn and shareholders' equity of ₹456.0m.
Vineet Laboratories Ltd. specializes in pharmaceutical intermediates and fine chemicals. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2021-06-15. The company specializes in pharmaceutical intermediates and fine chemicals. Its active pharmaceutical ingredient (API) intermediates include Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, and Piroctone Olanine. Its fine chemicals and reagents include Isopropyl-beta-D-thiogalactopyranoside, 4-Nitrophenyl phosphate disodium salt, 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal), 5-Acetyl thiophene-2-carboxilic acid, n-Butyl Lithium, n-Butyl magnesium chloride, 3-Furaldehyde, 3-bromofuran, 1-methyl-imidazole-2-carboxaldehyde, 6-Aminouracil, Ethyldiazo acetate, and Phenylboronic acid. The company also exports API intermediates, fine chemicals, and custom synthesis molecules.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Jun 2021
- Website
- vineetlabs.co.in ↗
Leadership
Pay as last reported
- Mr. Satyanarayana BhupathirajuChief Financial Officer, Whole Time Director, since 2021₹2.7m
- Mr. Rameshkumar BandariCompliance Officer, Company Secretary
- Mr. Gaddam RamanaManaging Director, Executive Director, since 2021₹3.3m
- Mr. Premananda VennapusaNon-Executive Director
- Mr. Dilip AcharekarNon-Executive Independent Director₹100,000
- Ms. Jasmin TailorNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vineet Laboratories specializes in API intermediates like Lopinavir and Ritonavir for HIV treatment.
- The company produces fine chemicals including Isopropyl-beta-D-thiogalactopyranoside for research applications.
- Vineet exports API intermediates and custom synthesis molecules globally to pharmaceutical markets.
Weaknesses
- Vineet's focus on API intermediates limits its product range compared to broader pharmaceutical companies.
- The company's reliance on specific chemicals like Glimepiride may expose it to market fluctuations.
- Vineet's small-scale operations in Hyderabad restrict its global manufacturing capacity.
Opportunities
- Expanding API intermediates to include new drugs like Efavirenz for HIV treatment.
- Growing demand for fine chemicals in research applications such as X-Gal and 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside.
- Increasing exports of custom synthesis molecules to meet global pharmaceutical needs.
Threats
- Competition from larger pharmaceutical companies in API intermediates market.
- Regulatory changes affecting the production of fine chemicals like n-Butyl Lithium.
- Economic downturns impacting the global pharmaceutical market for API intermediates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.